 |
 |
 |
||
|
||||
 |
|
| Updated Jul. 14, 2010 |
|
||||||||
 |
|
 |
|
 |
|
 |
|
 |
|
||||||||
|
||||||||||
The Supply and Demand for Antibiotics: Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia as an Example |
||||||||||
|
BARRY EISENSTEIN, MD, FACP, FIDSA Senior VP, Scientific Affairs Cubist Pharmaceuticals Clinical Professor of Medicine Harvard Medical School Boston, Massachusetts The initiation of the antibiotic era 7 decades ago led to extraordinary progress in the treatment of serious and often fatal bacterial infections. In the early part of that era, however, there was a lack of appreciation for mutation, genetic transfer, and Darwinian selection of resistant bacteria by the use (and overuse) of antibiotics. As a result, for decades, physicians were relatively indiscriminate in routinely using antibiotics for even trivial infections (many caused by viruses), which led to inappropriate expectations of their use by patients. PDF Download: The Supply and Demand for Antibiotics: Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia as an Example (Acrobat Reader is required)
|
||||||||||
| ** This site offers a selection of articles from the current issue. For access to complete content, make sure you are receiving the print edition of Infectious Disease Special Edition. Click here for a free subscription. | ||||||||||
 send a comment to the editor |  printer friendly |  email this article | back to top |
||||||||||
| More special edition | ||||||||||
|
||||||||||
 Special Edition Archives |
| home | about us | advertise | contact | publications |